

Table S3. Demographics of patients with wild-type (wt) and mutant (mut) *Rb1*.

		Wt (n = 471)	Mut (n = 131)	P
Median age		59 (19-90)	57 (31-92)	.92
Female		263 (55.8)	87 (66.4)	.03
Race	Asian	92 (19.5)	23 (17.6)	.70
	Black	20 (4.2)	5 (3.8)	
	Hispanic	75 (19.3)	18 (11.8)	
	White	265 (56.3)	82 (62.6)	
	Others	19 (4.0)	3 (2.3)	
PS	0-1	408 (86.4)	114 (87.0)	.86
	2-4	45 (9.6)	11 (8.4)	
	Unknown	18 (3.8)	6 (4.6)	
CCI		1 (0-9)	1 (0-7)	.01
Treatment	Yes	360 (76.4)	114 (87.0)	.007
	No	111 (23.6)	17 (13.0)	
Histology	LMS	96 (20.4)	78 (59.5)	< .001
	UPS	109 (23.1)	27 (20.6)	
	LPS	69 (14.6)	9 (6.9)	
	Others	197 (41.8)	17 (13.0)	
<i>CDKN2A</i>	wt	334 (70.9)	129 (98.5)	< .001
	mut	137 (29.1)	2 (1.5)	
<i>TP53</i>	wt	283 (60.1)	23 (17.6)	< .001
	mut	188 (39.1)	108 (82.4)	
<i>PTEN</i>	wt	440 (93.4)	105 (80.2)	< .001
	mut	31 (6.6)	26 (19.8)	
<i>ATRX</i>	wt	317 (67.3)	63 (48.1)	< .001
	mut	30 (6.4)	37 (28.2)	
	unknown	124 (26.3)	31 (23.7)	

Note: PS, performance status; CCI, Charlson comorbidity index; LMS, leiomyosarcoma; UPS, undifferentiated pleomorphic sarcoma; LPS, liposarcoma. The number inside the parenthesis represents percent except for median age.